Study Finds Opto-Acoustic Imaging During Neoadjuvant Therapy Correlates to Pathologic Response
Study Finds Opto-Acoustic Imaging During Neoadjuvant Therapy Correlates to Pathologic Response
08 déc. 2023 14h00 HE | Seno Medical
San Antonio, Texas, Dec. 08, 2023 (GLOBE NEWSWIRE) -- A limited feasibility study presented at this year’s San Antonio Breast Cancer Symposium (SABCS) found that Seno Medical’s Imagio® Breast...
Celcuity+Logo.jpg
Celcuity Presents Preclinical Data on Therapeutic Effects of Gedatolisib in Breast Cancer Models at the 2023 San Antonio Breast Cancer Symposium
06 déc. 2023 08h30 HE | Celcuity Inc.
MINNEAPOLIS, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today presented data from...
arvinas_logoART_lg.jpg
Arvinas to Host Conference Call and Webcast to Discuss Vepdegestrant (ARV-471) Data Presented at 2023 San Antonio Breast Cancer Symposium and Plans to Expand Vepdegestrant Development Program
05 déc. 2023 22h52 HE | Arvinas Inc.
NEW HAVEN, Conn., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
arvinas_logoART_lg.jpg
Arvinas and Pfizer Announce Interim Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®) and Plans to Expand Vepdegestrant Development Program
05 déc. 2023 13h33 HE | Arvinas Inc.
– Overall response rate of 42% and median progression-free survival of 11.1 months in heavily pre-treated patients (after 11 months median follow-up time and based on 48% of events) demonstrates the...
Olema_Oncology_HIGH RES LOGO.png
Olema Oncology Announces Palazestrant Demonstrates Attractive Combinability with CDK4/6 Inhibitors Ribociclib and Palbociclib in Phase 1b/2 Studies
05 déc. 2023 12h27 HE | Olema Oncology
Palazestrant (OP-1250) in combination with the CDK 4/6 inhibitors, ribociclib and palbociclib, demonstrated no significant drug-drug interaction, no dose-limiting toxicities and a tolerability profile...
SABCS Logo
PreludeDx to Present New Data on the Clinical Utility of DCISionRT in Australian Patients with DCIS at the 2023 San Antonio Breast Cancer Symposium
05 déc. 2023 07h00 HE | PreludeDx
In data presented at SABCS23, DCISionRT changed radiation therapy decisions in 41% of DCIS patients
Celcuity+Logo.jpg
Celcuity to Present Preclinical Data for Gedatolisib at the 2023 San Antonio Breast Cancer Symposium
01 déc. 2023 11h02 HE | Celcuity Inc.
MINNEAPOLIS, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that an...
SABCS Logo
PreludeDx to Present Data for a Novel Molecular Biosignature to Predict Radiation Therapy Benefit in Early-Stage Invasive Breast Cancer at the 2023 San Antonio Breast Cancer Symposium
29 nov. 2023 07h00 HE | PreludeDx
PreludeDx to Present Data for a Novel Molecular Biosignature to Predict Radiation Therapy Benefit in Early-Stage Invasive Breast Cancer at the 2023 SABCS
arvinas_logoART_lg.jpg
Arvinas and Pfizer Announce Updated Vepdegestrant (ARV-471) Data to be Presented at the 2023 San Antonio Breast Cancer Symposium
28 nov. 2023 17h05 HE | Arvinas Inc.
-- Six abstracts have been accepted for presentation, including updated data on vepdegestrant alone and in combination with palbociclib (IBRANCE®) -- NEW HAVEN, Conn. and NEW YORK, Nov. 28,...
logo.png
Data Demonstrating Precede Biosciences' Ability to Determine HER2 Status from 1mL of Plasma to be Presented at the 2023 San Antonio Breast Cancer Symposium
28 nov. 2023 17h02 HE | Precede Biosciences, Inc.
BOSTON, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Precede Biosciences, a company impacting the development and use of precision medicines with a first-in-class liquid biopsy platform, announces that data...